Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

Overview of attention for article published in Nature Medicine, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 50 news outlets
blogs: 7 blogs
twitter: 117 X users

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
reddit: 3 Redditors

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 8 posts from 7 blogs.

Lixosicone

New Drug Approvals, 24 Jun 2026

Lixosicone CAS 1610878-71-1 MF C29H40O3 MW 436.6 g/mol 1-[(3S,8S,9S,10R,13S,14S,17S)-3-[(4-methoxyphenyl)methoxy]-10,13…

Avancées marquantes à l’Inserm en 2023: les neurosciences bordelaises remarquées

Bordeaux Neurocampus, 29 Jan 2024

Travaux d'Erwan Bézard (IMN), PierVi Piazza (AelisFarma) et les équipes de Giovanni Marsicano et Jean-Michel Revest (Magendie…

A new pharmacological class for the treatment of cannabis addiction

Bordeaux Neurocampus, 14 Jun 2023

A scientific discovery by Aelis Farma with researchers from the Neurocentre Magendie and Columbia University (NY) in Nature…

‘Promising results’ for pill to treat cannabis use disorder that affects up to 30% of users

Whats New, 12 Jun 2023

WhatsNew2Day - Latest News And Breaking…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 4 additional blog posts.